Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

O. Dogar, A. Keding, R. Gabe, AM. Marshall, R. Huque, D. Barua, R. Fatima, A. Khan, R. Zahid, S. Mansoor, D. Kotz, M. Boeckmann, H. Elsey, E. Kralikova, S. Parrott, J. Li, A. Readshaw, A. Sheikh, K. Siddiqi, TB and Tobacco Consortium,

. 2020 ; 8 (11) : e1408-e1417. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027691

Grantová podpora
MC_PC_19004 Medical Research Council - United Kingdom

BACKGROUND: Smoking cessation is important in patients with tuberculosis because it can reduce the high rates of treatment failure and mortality. We aimed to assess the effectiveness and safety of cystine as a smoking cessation aid in patients with tuberculosis in Bangladesh and Pakistan. METHODS: We did a randomised, double-blind, placebo-controlled, trial at 32 health centres in Bangladesh and Pakistan. Eligible patients were adults (aged >18 years in Bangladesh; aged >15 years in Pakistan) with pulmonary tuberculosis diagnosed in the previous 4 weeks, who smoked tobacco on a daily basis and were willing to stop smoking. Patients were randomly assigned (1:1) to receive behavioural support plus either oral cytisine (9 mg on day 0, which was gradually reduced to 1·5 mg by day 25) or placebo for 25 days. Randomisation was done using pregenerated block randomisation lists, stratified by trial sites. Investigators, clinicians, and patients were masked to treatment allocation. The primary outcome was continuous abstinence at 6 months, defined as self-report (of not having used more than five cigarettes, bidis, a water pipe, or smokeless tobacco products since the quit date), confirmed biochemically by a breath carbon monoxide reading of less than 10 parts per million. Primary and safety analysis were done in the intention-to-treat population. This trial is registered with the International Standard Randomised Clinical Trial Registry, ISRCTN43811467, and enrolment is complete. FINDINGS: Between June 6, 2017, and April 30, 2018, 2472 patients (1527 patients from Bangladesh; 945 patients from Pakistan) were enrolled and randomly assigned to receive cytisine (n=1239) or placebo (n=1233). At 6 months, 401 (32·4%) participants in the cytisine group and 366 (29·7%) participants in the placebo group had achieved continuous abstinence (risk difference 2·68%, 95% CI -0·96 to 6·33; relative risk 1·09, 95% CI 0·97 to 1·23, p=0·114). 53 (4·3%) of 1239 participants in the cytisine group and 46 (3·7%) of 1233 participants in the placebo group reported serious adverse events (94 events in the cytisine group and 90 events in the placebo group), which included 91 deaths (49 in the cytisine group and 42 in the placebo group). None of the adverse events were attributed to the study medication. INTERPRETATION: Our findings do not support the addition of cytisine to brief behavioural support for the treatment of tobacco dependence in patients with tuberculosis. FUNDING: European Union Horizon 2020 and Health Data Research UK. TRANSLATIONS: For the Bengali and Urdu translations of the abstract see Supplementary Materials section.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027691
003      
CZ-PrNML
005      
20210114152231.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2214-109X(20)30312-0 $2 doi
035    __
$a (PubMed)33069301
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dogar, Omara $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK; Usher Institute, University of Edinburgh, Edinburgh, UK. Electronic address: omara.dogar@york.ac.uk.
245    10
$a Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial / $c O. Dogar, A. Keding, R. Gabe, AM. Marshall, R. Huque, D. Barua, R. Fatima, A. Khan, R. Zahid, S. Mansoor, D. Kotz, M. Boeckmann, H. Elsey, E. Kralikova, S. Parrott, J. Li, A. Readshaw, A. Sheikh, K. Siddiqi, TB and Tobacco Consortium,
520    9_
$a BACKGROUND: Smoking cessation is important in patients with tuberculosis because it can reduce the high rates of treatment failure and mortality. We aimed to assess the effectiveness and safety of cystine as a smoking cessation aid in patients with tuberculosis in Bangladesh and Pakistan. METHODS: We did a randomised, double-blind, placebo-controlled, trial at 32 health centres in Bangladesh and Pakistan. Eligible patients were adults (aged >18 years in Bangladesh; aged >15 years in Pakistan) with pulmonary tuberculosis diagnosed in the previous 4 weeks, who smoked tobacco on a daily basis and were willing to stop smoking. Patients were randomly assigned (1:1) to receive behavioural support plus either oral cytisine (9 mg on day 0, which was gradually reduced to 1·5 mg by day 25) or placebo for 25 days. Randomisation was done using pregenerated block randomisation lists, stratified by trial sites. Investigators, clinicians, and patients were masked to treatment allocation. The primary outcome was continuous abstinence at 6 months, defined as self-report (of not having used more than five cigarettes, bidis, a water pipe, or smokeless tobacco products since the quit date), confirmed biochemically by a breath carbon monoxide reading of less than 10 parts per million. Primary and safety analysis were done in the intention-to-treat population. This trial is registered with the International Standard Randomised Clinical Trial Registry, ISRCTN43811467, and enrolment is complete. FINDINGS: Between June 6, 2017, and April 30, 2018, 2472 patients (1527 patients from Bangladesh; 945 patients from Pakistan) were enrolled and randomly assigned to receive cytisine (n=1239) or placebo (n=1233). At 6 months, 401 (32·4%) participants in the cytisine group and 366 (29·7%) participants in the placebo group had achieved continuous abstinence (risk difference 2·68%, 95% CI -0·96 to 6·33; relative risk 1·09, 95% CI 0·97 to 1·23, p=0·114). 53 (4·3%) of 1239 participants in the cytisine group and 46 (3·7%) of 1233 participants in the placebo group reported serious adverse events (94 events in the cytisine group and 90 events in the placebo group), which included 91 deaths (49 in the cytisine group and 42 in the placebo group). None of the adverse events were attributed to the study medication. INTERPRETATION: Our findings do not support the addition of cytisine to brief behavioural support for the treatment of tobacco dependence in patients with tuberculosis. FUNDING: European Union Horizon 2020 and Health Data Research UK. TRANSLATIONS: For the Bengali and Urdu translations of the abstract see Supplementary Materials section.
650    _2
$a dospělí $7 D000328
650    _2
$a alkaloidy $x terapeutické užití $7 D000470
650    _2
$a azociny $x terapeutické užití $7 D001392
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a psychoterapie krátká $7 D011614
650    _2
$a chinoliziny $x terapeutické užití $7 D011807
650    _2
$a odvykání kouření $x metody $7 D016540
650    _2
$a poruchy vyvolané užíváním tabáku $x psychologie $x terapie $7 D014029
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tuberkulóza $x epidemiologie $7 D014376
651    _2
$a Bangladéš $x epidemiologie $7 D001459
651    _2
$a Pákistán $x epidemiologie $7 D010154
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Keding, Ada $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Gabe, Rhian $u Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
700    1_
$a Marshall, Anna-Marie $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Huque, Rumana $u ARK Foundation, Dhaka, Bangladesh; Department of Economics, University of Dhaka, Dhaka, Bangladesh.
700    1_
$a Barua, Deepa $u ARK Foundation, Dhaka, Bangladesh.
700    1_
$a Fatima, Razia $u Common Management Unit (TB, HIV/AIDS and Malaria), Islamabad, Pakistan.
700    1_
$a Khan, Amina $u The Initiative, Islamabad, Pakistan.
700    1_
$a Zahid, Raana $u The Initiative, Islamabad, Pakistan.
700    1_
$a Mansoor, Sonia $u Institute of Psychiatry, Rawalpindi Medical University, Rawalpindi, Pakistan.
700    1_
$a Kotz, Daniel $u Usher Institute, University of Edinburgh, Edinburgh, UK; Addiction Research and Clinical Epidemiology Unit, Institute of General Practice, Centre for Health and Society, Heinrich-Heine-University, Düsseldorf, Germany; Department of Family Medicine, Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands.
700    1_
$a Boeckmann, Melanie $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK; Addiction Research and Clinical Epidemiology Unit, Institute of General Practice, Centre for Health and Society, Heinrich-Heine-University, Düsseldorf, Germany; Department of Environment and Health, School of Public Health, Bielefeld University, Bielefeld, Germany.
700    1_
$a Elsey, Helen $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Kralikova, Eva $u 3rd Medical Department, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Parrott, Steve $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Li, Jinshuo $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Readshaw, Anne $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK.
700    1_
$a Sheikh, Aziz $u Usher Institute, University of Edinburgh, Edinburgh, UK.
700    1_
$a Siddiqi, Kamran $u Department of Health Sciences, Faculty of Sciences, University of York, York, UK; Hull York Medical School, University of York, York, UK.
710    2_
$a TB and Tobacco Consortium
773    0_
$w MED00188826 $t The Lancet. Global health $x 2214-109X $g Roč. 8, č. 11 (2020), s. e1408-e1417
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33069301 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152229 $b ABA008
999    __
$a ok $b bmc $g 1608026 $s 1118871
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 11 $d e1408-e1417 $e - $i 2214-109X $m The Lancet Global health $n Lancet Glob Health $x MED00188826
GRA    __
$a MC_PC_19004 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20210105
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace